CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
Copper Quest Announces Fully Subscribed Private Placement with Continued Support by Strategic International Investor
LaFleur Minerals Appoints Andrew Elinesky as Chief Executive Officer and Provides Update on Beacon Gold Mill Recommissioning Work and Swanson Bulk Sample Progress
